Sioux Honey and Food City Partner for Record Honey Donation
Children's charities in Virginia & Tennessee receive gift - and sweet lesson, too
Johnson City, Tennessee--(Newsfile Corp. - March 12, 2025) - The Sioux Honey Association Co-op is pleased to announce its participation at the Coalition For Kids after-school program alongside a group of about 50 children during in an interactive lesson on honey and honeybee pollination on Wednesday.
The event at the Johnson City nonprofit was part of a broader effort to make a record donation of honey by the Sioux Honey Association Co-op, a beekeeper-owned group of 175+ beekeepers, that was joined by regional grocer Food City to donate 2½ tons of SUE BEE® clover honey to three child-focused organizations: Coalition For Kids; Boys & Girls Clubs of the Tennessee Valley in Knoxville; and Mountain Mission School in Grundy, Va.
The honey will be used as part of meals and snacks for after-school programs, organizers said. The donation of 540 cases (with 6,480 bottles of honey) was divided evenly among the three nonprofits.
'It's a ton of honey - actually about two-and-a-half tons,' said Kevin Hueser, President & CEO of the Sioux Honey Co-op. 'But it will go fast; it should certainly be gone before the three-year expiration date for honey passes.'
On Wednesday, children at Coalition For Kids learned about worker bees, drone bees and queen bees, as well as how honeybees help pollinate everyday foods, such as almonds, melons and avocados.
To demonstrate the pollination process, children played 'honeybees,' with yellow cotton balls while other students portrayed 'flowers' by holding cups filled with different-colored glitter. The children learned how honeybees carry pollen from flower to flower, and how cross-pollination happens as pollens mix.
'It was a fun exercise for our after-school kids,' said Randy Hensley, Executive Director at Coalition For Kids. 'And the honey donation will help with snacks for the kids in our after-school programs.'
Said Chris Mitchell, President at Mountain Mission School: 'As a beekeeper myself, I understand the importance of this process of nature; honeybee pollination is an essential part of the food production process.'
Wednesday's donations to the three child-focused organizations are just one of several donation efforts planned by the Sioux Honey Co-op in 2025. More donations will be coming later this summer following the honey harvest season.
'As beekeepers, we are passionate not only about our honey, but also about giving back to the communities we serve,' said David Coy, a third-generation Sioux Honey Co-op beekeeper whose family tends to beehives in Perkinston, Miss., and Hebron, N.D.
More than 50 students who take part in the Coalition For Kids after-school program in Johnson City, participated Wednesday in an interactive and hands-on lesson about honeybees and how honeybee pollination works. The event was part of a large honey donation made by the Sioux Honey Association Co-op and Food City.
A donation of 2,160 bottles of SUE BEE® honey was made to Coalition For Kids in Johnson City on Wednesday by the Sioux Honey Association Co-op and Food City.
To view an enhanced version of this graphic, please visit:
[ This image cannot be displayed. Please visit the source: ]
To view an enhanced version of this graphic, please visit:
ABOUT SIOUX HONEY: In 1921, the Sioux Honey Co-op began as a small group of just five beekeepers. Located near Sioux City, Iowa, they shared equipment, marketing and processing facilities - all to help support one another. Today, Sioux Honey is still a co-op, but it has grown into 175+ beekeepers nationwide. Some have been members for decades - part of families who have passed down the trade for generations - and some have pioneered and started their own bee farms. But all of the members have a passion for producing a pure, quality product that customers can trust. And we're proud to say we know each of our beekeepers by name, because we've learned that's how you produce the best honey for more than a century.
ABOUT FOOD CITY: Headquartered in Abingdon, Virginia, K-VA-T Food Stores (Food City's parent company) operates 158 retail outlets throughout southeast Kentucky, southwest Virginia, east Tennessee, north Georgia, and Alabama.
402-740-8188
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio


Business Wire
10 hours ago
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit


Business Upturn
13 hours ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.